WITHDRAWN: Potential Therapeutic Targets Screening for Esophageal Squamous Cell Carcinoma Via Combined Analysis of Genomic Sequencing Data and Target Pharmacophore Database
Ling Zhang,Feng Liu,Yanghui Bi,Heyang Cui,Pengzhou Kong,Jiayi Li,Bin Song,Binbin Zou,Caixia Cheng,Ting Yan,Jian Yang,Yu Qian,Yanchun Ma,Fang Wang,Hongyi Li,Zhiwu Jia,Xiaoling Hu,Bin Yang,Enwei Xu,Yaoping Li,Juan Wang,Jie Yang,Yuanfang Zhai,Yiqian Liu,Lu Chang,Yi Wang,Yingchun Zhang,Ruyi Shi,Junmei Jia,Jing Liu,Xiaolong Cheng,Yongping Cui
DOI: https://doi.org/10.18632/oncotarget.24052
2018-01-01
Oncotarget
Abstract:// Ling Zhang 1,2,3,* , Feng Liu 4,* , Yanghui Bi 1,2,* , Heyang Cui 1,2,* , Pengzhou Kong 1,2,* , Jiayi Li 5,* , Bin Song 1,6 , Binbin Zou 1,2 , Caixia Cheng 1,7 , Ting Yan 1,2 , Jian Yang 1,2 , Yu Qian 1,2 , Yanchun Ma 1,2 , Fang Wang 1,2 , Hongyi Li 1,2 , Zhiwu Jia 1,2 , Xiaoling Hu 1,2 , Bin Yang 1,2,8 , Enwei Xu 1,2,9 , Yaoping Li 1,2,10 , Juan Wang 1,2 , Jie Yang 1,2 , Yuanfang Zhai 1,2 , Yiqian Liu 1,2 , Lu Chang 1,2 , Yi Wang 1,2 , Yingchun Zhang 1,2 , Ruyi Shi 1,2 , Junmei Jia 6 , Jing Liu 11 , Xiaolong Cheng 1,2,12 and Yongping Cui 1,2 1 Translational Medicine Research Center, Shanxi Medical University, Taiyuan, Shanxi, China 2 Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, Shanxi, China 3 Department of Pathology, Shanxi Medical University, Taiyuan, Shanxi, China 4 Department of Forensic, Shanxi Medical University, Taiyuan, Shanxi, China 5 Anglo-Chinese School (Independent), Singapore 6 Department of Oncology, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi, China 7 Department of Pathology, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi, China 8 Department of Tumor Surgery, Shanxi Cancer Hospital, Taiyuan, Shanxi, China 9 Department of Pathology, Shanxi Cancer Hospital, Taiyuan, Shanxi, China 10 Department of Anorectum, Shanxi Provincial People’s Hospital, Taiyuan, Shanxi, China 11 Department of General Surgery, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi, China 12 Department of Anatomy, Shanxi Medical University, Taiyuan, Shanxi, China * These authors have contributed equally to this work Correspondence to: Yongping Cui, email: cuiyp@sxmu.edu.cn Keywords : therapeutic targets; genomic sequencing; mutated genes; copy number alterations; ESCC Received: January 23, 2017 Accepted: December 28, 2017 Epub: January 09, 2018 Abstract Esophageal squamous cell carcinoma (ESCC) is the eighth most common and the sixth most lethal cancer worldwide with approximately 70% occurrence in China. Recently, tremendous progress has been made in cancer genomics including ESCC. However, the clinical significance of genetic abnormalities of ESCC remains poorly defined and no reliable therapeutic targets have been identified. Here, we analyzed genomic sequencing data from 469 ESCC cases and screened potential therapeutic targets in DGIdb and other databases. We identified a series of therapeutic targeted genes such as NOTCH1 , LRP1B , PIK3CA , CDKN2A , ERBB4 , ABCB1 , ABL1 , KDR , AKT1 , CCND1 , CDK6 , CPT1A , EGFR , ERBB2 . Furthermore, KEGG enrichment analyses of all druggable genes by DAIVD revealed that the significantly altered pathways including RTK-RAS, PI3K/AKT/mTOR, ERBB, NOTCH signaling pathway, cell cycle, and proteasome may be promising therapeutic targets for ESCC patients. Of these pathways, treatment of ESCC cells with specific inhibitor targeting RTK-RAS signaling pathway or proteasome exhibits significant prevention of cell growth, supporting the possibility of therapeutic strategy of targeting these signaling pathways in ESCC. Notably, targeting KDR over-expression in endothelial and cancer cells may be an effective way to treat ESCC cases not only with KDR variant but also with ZNF750 mutation and deletion individuals. Collectively, our study linked genomic alterations to potential therapeutic options in ESCC and identified a set of targetable genes and associated drugs for treatment of ESCC. Consequent results may extend our knowledge to potential druggable targets in a segment of ESCC patients, which may guide the therapeutic strategy to combat ESCC.